Snus use and rejection in the USA
- PMID: 24570100
- PMCID: PMC4519419
- DOI: 10.1136/tobaccocontrol-2013-051342
Snus use and rejection in the USA
Abstract
Objective: To determine whether snus might become a strategy for reducing the harm associated with cigarette smoking in the USA as appears to be the case in Sweden, we examined receptivity to snus use in two cities with the greatest exposure to the major brands.
Methods: A dual frame, telephone survey and a brief mail survey were conducted in 2011 and 2012 in Indianapolis, Indiana and Dallas/Fort Worth Texas. Over 5000 adults completed surveys. Trial, ever use, current use and reasons for using or quitting snus after trial were measured.
Results: Among male smokers, 29.9% had ever tried snus (CI 22.7 to 38.1) and 4.2% were current users (CI 1.6 to 10.7). Among female smokers, 8.5% ever tried snus (CI 4.4 to 15.7) and current use was unknown. Current use was virtually absent among former smokers and never smokers. A major predictor of any level of snus use was current use of conventional smokeless tobacco. Those who tried and gave up snus cited curiosity (41.3%) and the fact that it was available at low or no cost (30%) as reasons for trial; reasons for not continuing included preferring another form of tobacco (75.1%) and disliking the mouth feel (34.6%). Almost all current snus users indicated that they were trying to cut down on cigarettes, but few (3.9%) were using it to quit smoking entirely.
Conclusions: The low rate of adoption of snus suggests that neither the hopes nor the fears surrounding this new product are likely to be realised in the USA with the current marketing patterns.
Keywords: Harm Reduction; Non-cigarette tobacco products; Public policy.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Conflict of interest statement
Dorothy Hatsukami received funding from Nabi Pharmaceuticals to be site for nicotine immunotherapy trial.
References
-
- Staff. Winston-Salem Journal. Winston-Salem; 2010. Altria Group to go national with smokeless Marlboro Snus.
-
- Craver R. Winston-Salem Journal. Winston-Salem; 2008. Reynolds is taking its snus national.
-
- Staff. Winston-Salem Journal. Winston-Salem; 2011. Lorillard CEO: No need to venture beyond cigs.
-
- Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiology Biomarkers Prev. 2004;13:2035–2042. - PubMed
-
- Luo J, Ye W, Zendehdel K, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: A restrospective cohort study. Lancet. 2007;369:2015–2020. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical